Grifols SA ADR(GRFS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 9.87 | EPS (ttm) | 0.77 | Insider Own | 0.06% | Shs Outstand | 258.2M | Perf Week | -2.3% |
| Market Cap | 1.98B | Forward P/E | 6.2 | EPS next Y | 29.97% | Insider Trans | - | Shs Float | 258.1M | Perf Month | -4.26% |
| Enterprise Value | 13.91B | PEG | 0.26 | EPS next Q | - | Inst Own | 56.45% | Short Float | 1.36% | Perf Quarter | 4.51% |
| Income | 0.53B | P/S | 0.23 | EPS this Y | 11.36% | Inst Trans | 3.93% | Short Ratio | 5.75 | Perf Half Y | -4.73% |
| Sales | 8.65B | P/B | 0.82 | EPS next 5Y | 23.87% | ROA | 2.28% | Short Interest | 3.52M | Perf YTD | -18.18% |
| Book/sh | 9.32 | P/C | 3.37 | EPS past 3/5Y | 27.36% -8.34% | ROE | 8.5% | 52W High | -25.22% ($10.23) | Perf Year | -22.34% |
| Cash/sh | 2.27 | P/FCF | 2.09 | Sales past 3/5Y | 10.04% 6.88% | ROIC | 3.38% | 52W Low | 9.91% ($6.96) | Perf 3Y | -14.33% |
| Dividend Est. | $0.27 (3.54%) | EV/EBITDA | 7.24 | EPS Y/Y TTM | 61.67% | Gross Margin | 36.98% | Volatility(W/M) | 1.73% 2.05% | Perf 5Y | -45.63% |
| Dividend TTM | 0.11 | EV/Sales | 1.61 | Sales Y/Y TTM | 6.84% | Oper. Margin | 16.23% | ATR (14) | 0.18 | Perf 10Y | -53.1% |
| Dividend Ex-Date | 2026/7/2 | Quick Ratio | 0.81 | EPS Q/Q | 34.78% | Profit Margin | 6.09% | RSI (14) | 43.79 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - -8.05% | Current Ratio | 2.37 | Sales Q/Q | 1.65% | SMA20 | -2.63% ($7.86) | Beta | 0.69 | Target Price | $12.93 |
| Payout | 34.22% | Debt/Eq | 1.54 | Earnings | 2026/7/28 | SMA50 | -0.8% ($7.71) | Rel Volume | 0.5 | Prev Close | $7.82 |
| Employees | 25258 | LT Debt/Eq | 1.46 | EPS/Sales Surpr. | -26.24% -6.1% | SMA200 | -7.49% ($8.27) | Avg Volume(3M) | 0.61M | Price | $7.65 |
| IPO | 2011/6/2 | Option/Short | Yes/Yes | Trades | 2188 | Volume | 302,562 | Change | -2.17% |
Company
GRFS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩸 A global pharmaceutical company that develops and manufactures plasma-derived therapies. It produces plasma protein therapeutics such as immunoglobulins, albumin, and coagulation factors extracted from human plasma, and also operates a worldwide plasma collection network along with a diagnostics business. The company has established itself as a pharmaceutical specialist in plasma medicines with a vertically integrated structure that spans from plasma collection to drug manufacturing.
Over the past 1 year, on the lower side
25% below its 1-year high.
GRFS has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.4% this year.
Tap to view numbers
The stock looks undervalued
Trading at 9.9 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -14.3% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.54% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 56.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BSMC 0.01%
EWP 0.01%
BINV 0.01%
MYHB 0.01%
VSHY 0.01%It ranks #4 in the industry
Based on market cap of $2B.
GRFS $2B PER 9.9
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is GRFS?
GRFS belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of GRFS?
The market cap of GRFS is approximately $2.0B, ranking 2,111 within its sector.
Does GRFS pay dividends?
GRFS has a dividend yield of approximately 3.54%, with an annual dividend of $0.27.
What is the P/E ratio of GRFS?
GRFS has a P/E ratio of approximately 9.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GRFS?
GRFS has recorded a 52-week high of $10.23 and a low of $6.96.
